Floatz logo

Tetrahydrouridine

Carcinoma, Esophageal

National Cancer Institute (NCI)Small moleculePhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

41 Active assets in the Carcinoma, Esophageal cohort.

Asset / SponsorPhaseRating
Pembrolizumab
NuCana plc
Phase 3BB
Docetaxel
NuCana plc
Phase 3BB
Irinotecan
Merck Sharp & Dohme LLC
Phase 3B
Capivasertib
National Cancer Institute (NCI)
Phase 2CCC
Thalidomide
Henan Cancer Hospital
Phase 2CCC

View all 50 →

Same molecule, other indications

Tetrahydrouridine is also rated in:

urinary bladder neoplasmDormant
B
Indicative ·
59 / 100
View asset →
head and neck neoplasmDormant
B
Indicative ·
58 / 100
View asset →
lung neoplasmDormant
CCC
Indicative ·
55 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →